HALOZYME THERAPEUTICS, INC. Research and Development Expense
HALOZYME THERAPEUTICS, INC. (HALO) reported Research and Development Expense of $27.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- HALOZYME THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $27.66M, a 57.69% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $25.56M, a 72.71% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $17.25M, a 6.54% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. research and development expense for the quarter ending 2025-06-30 was $17.54M, a 16.61% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. research and development expense for fiscal 2024 was $79.05M, a 3.52% increase from fiscal 2023.
- HALOZYME THERAPEUTICS, INC. research and development expense for fiscal 2023 was $76.36M, a 14.65% increase from fiscal 2022.
- HALOZYME THERAPEUTICS, INC. research and development expense for fiscal 2022 was $66.61M, a 86.72% increase from fiscal 2021.
- HALOZYME THERAPEUTICS, INC. research and development expense for fiscal 2021 was $35.67M, a 4.19% increase from fiscal 2020.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $27.66M 10-Q · filed 2026-08-06 | $53.22M 10-Q · filed 2026-08-06 | ||||||
| 2026-03-31 | $25.56M 10-Q · filed 2026-05-11 | |||||||
| 2025-09-30 | $17.25M 10-Q · filed 2025-11-03 | $34.79M derived: sum of 2 quarters · filed 2026-08-06 | $49.59M 10-Q · filed 2025-11-03 | $70.03M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $17.54M 10-Q · filed 2026-08-06 | $32.34M 10-Q · filed 2026-08-06 | $52.78M derived: sum of 3 quarters · filed 2026-08-06 | $71.24M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $14.80M 10-Q · filed 2026-05-11 | $35.24M derived: sum of 2 quarters · filed 2026-05-11 | $53.70M derived: sum of 3 quarters · filed 2026-05-11 | $74.74M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $20.44M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $38.90M derived: sum of 2 quarters · filed 2025-11-03 | $59.94M derived: sum of 3 quarters · filed 2025-11-03 | $79.05M 10-K · filed 2025-02-18 | ||||
| 2024-09-30 | $18.46M 10-Q · filed 2025-11-03 | $39.50M derived: sum of 2 quarters · filed 2025-11-03 | $58.61M 10-Q · filed 2025-11-03 | $79.94M derived: sum of 4 quarters · filed 2025-11-03 | ||||
| 2024-06-30 | $21.04M 10-Q · filed 2025-08-05 | $40.15M 10-Q · filed 2025-08-05 | $61.48M derived: sum of 3 quarters · filed 2025-08-05 | $78.81M derived: sum of 4 quarters · filed 2025-08-05 | ||||
| 2024-03-31 | $19.11M 10-Q · filed 2025-05-06 | $40.45M derived: sum of 2 quarters · filed 2025-05-06 | $57.77M derived: sum of 3 quarters · filed 2025-05-06 | $77.50M derived: sum of 4 quarters · filed 2025-05-06 | ||||
| 2023-12-31 | $21.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $38.66M derived: sum of 2 quarters · filed 2025-02-18 | $58.38M derived: sum of 3 quarters · filed 2025-02-18 | $76.36M 10-K · filed 2025-02-18 | ||||
| 2023-09-30 | $17.32M 10-Q · filed 2024-10-31 | $37.05M derived: sum of 2 quarters · filed 2024-10-31 | $55.03M 10-Q · filed 2024-10-31 | $77.59M derived: sum of 4 quarters · filed 2025-02-18 | ||||
| 2023-06-30 | $19.73M 10-Q · filed 2024-08-06 | $37.71M 10-Q · filed 2024-08-06 | $60.27M derived: sum of 3 quarters · filed 2025-02-18 | $76.98M derived: sum of 4 quarters · filed 2025-02-18 | ||||
| 2023-03-31 | $17.98M 10-Q · filed 2024-05-07 | $40.55M derived: sum of 2 quarters · filed 2025-02-18 | $57.25M derived: sum of 3 quarters · filed 2025-02-18 | $72.73M derived: sum of 4 quarters · filed 2025-02-18 | ||||
| 2022-12-31 | $22.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $39.27M derived: sum of 2 quarters · filed 2025-02-18 | $54.75M derived: sum of 3 quarters · filed 2025-02-18 | $66.61M 10-K · filed 2025-02-18 | ||||
| 2022-09-30 | $16.70M 10-Q · filed 2023-11-06 | $32.19M derived: sum of 2 quarters · filed 2023-11-06 | $44.04M 10-Q · filed 2023-11-06 | $54.15M derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2022-06-30 | $15.48M 10-Q · filed 2023-08-08 | $27.34M 10-Q · filed 2023-08-08 | $37.44M derived: sum of 3 quarters · filed 2024-02-20 | $45.93M derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2022-03-31 | $11.85M 10-Q · filed 2023-05-09 | $21.96M derived: sum of 2 quarters · filed 2024-02-20 | $30.45M derived: sum of 3 quarters · filed 2024-02-20 | $38.52M derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2021-12-31 | $10.11M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $18.59M derived: sum of 2 quarters · filed 2024-02-20 | $26.66M derived: sum of 3 quarters · filed 2024-02-20 | $35.67M 10-K · filed 2024-02-20 | ||||
| 2021-09-30 | $8.49M 10-Q · filed 2022-11-08 | $16.55M derived: sum of 2 quarters · filed 2022-11-08 | $25.56M 10-Q · filed 2022-11-08 | $32.94M derived: sum of 4 quarters · filed 2023-02-21 | ||||
| 2021-06-30 | $8.07M 10-Q · filed 2022-08-09 | $17.08M 10-Q · filed 2022-08-09 | $24.46M derived: sum of 3 quarters · filed 2023-02-21 | $32.20M derived: sum of 4 quarters · filed 2023-02-21 | ||||
| 2021-03-31 | $9.01M 10-Q · filed 2022-05-10 | $16.39M derived: sum of 2 quarters · filed 2023-02-21 | $24.14M derived: sum of 3 quarters · filed 2023-02-21 | $33.09M derived: sum of 4 quarters · filed 2023-02-21 | ||||
| 2020-12-31 | $7.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $15.13M derived: sum of 2 quarters · filed 2023-02-21 | $24.08M derived: sum of 3 quarters · filed 2023-02-21 | $34.24M 10-K · filed 2023-02-21 | ||||
| 2020-09-30 | $7.75M 10-Q · filed 2021-11-02 | $16.70M derived: sum of 2 quarters · filed 2021-11-02 | $26.86M 10-Q · filed 2021-11-02 | $71.97M derived: sum of 4 quarters · filed 2022-02-22 | ||||
| 2020-06-30 | $8.95M 10-Q · filed 2021-08-09 | $19.11M 10-Q · filed 2021-08-09 | $64.22M derived: sum of 3 quarters · filed 2022-02-22 | $94.67M derived: sum of 4 quarters · filed 2022-02-22 | ||||
| 2020-03-31 | $10.16M 10-Q · filed 2021-05-10 | $55.27M derived: sum of 2 quarters · filed 2022-02-22 | $85.72M derived: sum of 3 quarters · filed 2022-02-22 | $119.63M derived: sum of 4 quarters · filed 2022-02-22 | ||||
| 2019-12-31 | $45.11M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $75.57M derived: sum of 2 quarters · filed 2022-02-22 | $109.48M derived: sum of 3 quarters · filed 2022-02-22 | $140.80M 10-K · filed 2022-02-22 | ||||
| 2019-09-30 | $30.45M 10-Q · filed 2020-11-02 | $64.36M derived: sum of 2 quarters · filed 2020-11-02 | $95.69M 10-Q · filed 2020-11-02 | $132.34M derived: sum of 4 quarters · filed 2021-02-23 | ||||
| 2019-06-30 | $33.91M 10-Q · filed 2020-08-10 | $65.24M 10-Q · filed 2020-08-10 | $101.89M derived: sum of 3 quarters · filed 2021-02-23 | $137.43M derived: sum of 4 quarters · filed 2021-02-23 | ||||
| 2019-03-31 | $31.33M 10-Q · filed 2020-05-11 | $67.98M derived: sum of 2 quarters · filed 2021-02-23 | $103.52M derived: sum of 3 quarters · filed 2021-02-23 | $143.60M derived: sum of 4 quarters · filed 2021-02-23 | ||||
| 2018-12-31 | $36.65M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $72.19M derived: sum of 2 quarters · filed 2021-02-23 | $112.28M derived: sum of 3 quarters · filed 2021-02-23 | $150.25M 10-K · filed 2021-02-23 | ||||
| 2018-09-30 | $35.54M 10-Q · filed 2019-11-12 | $75.63M derived: sum of 2 quarters · filed 2019-11-12 | $113.60M 10-Q · filed 2019-11-12 | $154.98M derived: sum of 4 quarters · filed 2020-02-24 | ||||
| 2018-06-30 | $40.09M 10-Q · filed 2019-08-06 | $78.06M 10-Q · filed 2019-08-06 | $119.44M derived: sum of 3 quarters · filed 2020-02-24 | $153.43M derived: sum of 4 quarters · filed 2020-02-24 | ||||
| 2018-03-31 | $37.98M 10-Q · filed 2019-05-07 | $79.35M derived: sum of 2 quarters · filed 2020-02-24 | $113.34M derived: sum of 3 quarters · filed 2020-02-24 | $151.68M derived: sum of 4 quarters · filed 2020-02-24 | ||||
| 2017-12-31 | $41.38M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $75.37M derived: sum of 2 quarters · filed 2020-02-24 | $113.71M derived: sum of 3 quarters · filed 2020-02-24 | $150.64M 10-K · filed 2020-02-24 | ||||
| 2017-09-30 | $33.99M 10-Q · filed 2018-11-06 | $72.33M derived: sum of 2 quarters · filed 2018-11-06 | $109.27M 10-Q · filed 2018-11-06 | $150.62M derived: sum of 4 quarters · filed 2019-02-21 | ||||
| 2017-06-30 | $38.34M 10-Q · filed 2018-08-07 | $75.27M 10-Q · filed 2018-08-07 | $116.62M derived: sum of 3 quarters · filed 2019-02-21 | $150.49M derived: sum of 4 quarters · filed 2019-02-21 | ||||
| 2017-03-31 | $36.94M 10-Q · filed 2018-05-10 | $78.28M derived: sum of 2 quarters · filed 2019-02-21 | $112.15M derived: sum of 3 quarters · filed 2019-02-21 | $147.68M derived: sum of 4 quarters · filed 2019-02-21 | ||||
| 2016-12-31 | $41.35M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | $75.21M derived: sum of 2 quarters · filed 2019-02-21 | $110.74M derived: sum of 3 quarters · filed 2019-02-21 | $150.84M 10-K · filed 2019-02-21 | ||||
| 2016-09-30 | $33.86M 10-Q · filed 2017-11-07 | $69.39M derived: sum of 2 quarters · filed 2017-11-07 | $109.49M 10-Q · filed 2017-11-07 | $137.24M derived: sum of 4 quarters · filed 2018-02-20 | ||||
| 2016-06-30 | $35.53M 10-Q · filed 2017-08-08 | $75.63M 10-Q · filed 2017-08-08 | $103.38M derived: sum of 3 quarters · filed 2018-02-20 | $130.99M derived: sum of 4 quarters · filed 2018-02-20 | ||||
| 2016-03-31 | $40.10M 10-Q · filed 2017-05-09 | $67.85M derived: sum of 2 quarters · filed 2018-02-20 | $95.46M derived: sum of 3 quarters · filed 2018-02-20 | $116.65M derived: sum of 4 quarters · filed 2018-02-20 | ||||
| 2015-12-31 | $27.75M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | $55.36M derived: sum of 2 quarters · filed 2018-02-20 | $76.55M derived: sum of 3 quarters · filed 2018-02-20 | $93.24M 10-K · filed 2018-02-20 | ||||
| 2015-09-30 | $27.61M 10-Q · filed 2016-11-07 | $48.81M derived: sum of 2 quarters · filed 2016-11-07 | $65.49M 10-Q · filed 2016-11-07 | $85.22M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2015-06-30 | $21.20M 10-Q · filed 2016-08-09 | $37.88M 10-Q · filed 2016-08-09 | $57.61M derived: sum of 3 quarters · filed 2017-02-28 | $77.51M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2015-03-31 | $16.68M 10-Q · filed 2016-05-09 | $36.41M derived: sum of 2 quarters · filed 2017-02-28 | $56.32M derived: sum of 3 quarters · filed 2017-02-28 | $74.97M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2014-12-31 | $19.73M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $39.63M derived: sum of 2 quarters · filed 2017-02-28 | $58.28M derived: sum of 3 quarters · filed 2017-02-28 | $79.70M 10-K · filed 2017-02-28 | ||||
| 2014-09-30 | $19.90M 10-Q · filed 2015-11-09 | $38.55M derived: sum of 2 quarters · filed 2015-11-09 | $59.97M 10-Q · filed 2015-11-09 | $80.89M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-06-30 | $18.65M 10-Q · filed 2015-08-10 | $40.06M 10-Q · filed 2015-08-10 | $60.99M derived: sum of 3 quarters · filed 2016-02-29 | $86.68M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-03-31 | $21.41M 10-Q · filed 2015-05-11 | $42.34M derived: sum of 2 quarters · filed 2016-02-29 | $68.03M derived: sum of 3 quarters · filed 2016-02-29 | $96.02M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2013-12-31 | $20.93M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $46.62M derived: sum of 2 quarters · filed 2016-02-29 | $74.61M derived: sum of 3 quarters · filed 2016-02-29 | $96.64M 10-K · filed 2016-02-29 | $96.64M 10-K · filed 2014-02-28 | |||
| 2013-09-30 | $25.69M 10-Q · filed 2014-11-10 | $25.69M 10-Q · filed 2013-11-08 | $53.68M derived: sum of 2 quarters · filed 2014-11-10 | $75.71M 10-Q · filed 2014-11-10 | $75.71M 10-Q · filed 2013-11-08 | $94.28M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-06-30 | $27.99M 10-Q · filed 2014-08-11 | $27.99M 10-Q · filed 2013-08-07 | $50.02M 10-Q · filed 2014-08-11 | $50.03M 10-Q · filed 2013-08-07 | $68.59M derived: sum of 3 quarters · filed 2015-03-02 | $88.10M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-03-31 | $22.03M 10-Q · filed 2014-05-12 | $22.03M 10-Q · filed 2013-05-08 | $40.60M derived: sum of 2 quarters · filed 2015-03-02 | $60.11M derived: sum of 3 quarters · filed 2015-03-02 | $76.19M derived: sum of 4 quarters · filed 2015-03-02 | |||
| 2012-12-31 | $18.57M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $38.07M derived: sum of 2 quarters · filed 2015-03-02 | $54.15M derived: sum of 3 quarters · filed 2015-03-02 | $70.04M 10-K · filed 2015-03-02 | $70.04M 10-K · filed 2013-03-01 | |||
| 2012-09-30 | $19.50M 10-Q · filed 2013-11-08 | $35.59M derived: sum of 2 quarters · filed 2013-11-08 | $51.48M 10-Q · filed 2013-11-08 | $66.39M derived: sum of 4 quarters · filed 2014-02-28 | ||||
| 2012-06-30 | $16.08M 10-Q · filed 2013-08-07 | $31.97M 10-Q · filed 2013-08-07 | $46.89M derived: sum of 3 quarters · filed 2014-02-28 | $60.40M derived: sum of 4 quarters · filed 2014-02-28 | ||||
| 2012-03-31 | $15.89M 10-Q · filed 2013-05-08 | $30.81M derived: sum of 2 quarters · filed 2014-02-28 | $44.32M derived: sum of 3 quarters · filed 2014-02-28 | $59.67M derived: sum of 4 quarters · filed 2014-02-28 | ||||
| 2011-12-31 | $14.92M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $28.43M derived: sum of 2 quarters · filed 2014-02-28 | $43.78M derived: sum of 3 quarters · filed 2014-02-28 | $57.56M 10-K · filed 2014-02-28 | ||||
| 2011-09-30 | $13.51M 10-Q · filed 2012-11-08 | $28.86M derived: sum of 2 quarters · filed 2012-11-08 | $42.65M 10-Q · filed 2012-11-08 | $58.58M derived: sum of 4 quarters · filed 2013-03-01 | ||||
| 2011-06-30 | $15.35M 10-Q · filed 2012-08-09 | $29.13M 10-Q · filed 2012-08-09 | $45.07M derived: sum of 3 quarters · filed 2013-03-01 | $57.51M derived: sum of 4 quarters · filed 2013-03-01 | ||||
| 2011-03-31 | $13.79M 10-Q · filed 2012-05-07 | $29.72M derived: sum of 2 quarters · filed 2013-03-01 | $42.17M derived: sum of 3 quarters · filed 2013-03-01 | $54.09M derived: sum of 4 quarters · filed 2013-03-01 | ||||
| 2010-12-31 | $15.93M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $28.38M derived: sum of 2 quarters · filed 2013-03-01 | $40.31M derived: sum of 3 quarters · filed 2013-03-01 | $51.77M 10-K · filed 2013-03-01 | ||||
| 2010-09-30 | $12.45M 10-Q · filed 2011-11-08 | $24.37M derived: sum of 2 quarters · filed 2011-11-08 | $35.84M 10-Q · filed 2011-11-08 | |||||
| 2010-06-30 | $11.92M 10-Q · filed 2011-08-05 | $23.39M 10-Q · filed 2011-08-05 | ||||||
| 2009-12-31 | $56.61M 10-K · filed 2012-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |